Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Huy Gia Vuong, An Thi Nhat Ho, Ahmed M A Altibi...
https://pubmed.ncbi.nlm.nih.gov/30089599/Actively Recruiting
Led by Haihe Biopharma Co., Ltd. · Updated on 2022-08-01
183
Participants Needed
44
Research Sites
9 weeks
Total Duration
This clinical trial is studying patients with advanced non-small cell lung cancer NSCLC who have specific alterations in the MET gene, including mutations and amplifications. The study focuses on evaluating the effects and safety of Glumetinib, a selective MET inhibitor, in adults with locally advanced or metastatic NSCLC, including pulmonary sarcomatoid carcinoma. This includes patients who have had prior treatments or are not eligible for chemotherapy. The trial is conducted in phases Ib and II with participants from China, the US, and globally. Participants receive Glumetinib orally at a dose of 300 mg once daily while fasting. The Phase Ib portion includes about 90 patients with various MET alterations, while Phase II involves around 78 patients who have METex14 skipping mutations and meet additional criteria related to prior treatments and chemotherapy eligibility. The study allows for a safety run-in group of at least six patients in the US. Treatment continues according to the study protocol to assess response and safety. Throughout the study, participants will undergo regular assessments to monitor tumor response using RECIST 1.1 criteria and to evaluate safety and side effects. Researchers will track objective response rate ORR over about one year, along with duration of response and overall efficacy. Patients must have adequate organ function and performance status to participate. The study includes follow-up visits to observe treatment effects and document any adverse events during and after the treatment period, with a total participation duration aligned with the study completion timeline.
CONDITIONS
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
S
Shun LU, Doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Haihe Biopharma Co., Ltd.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Glumetinib (oral MET inhibitor) | Platinum-based chemotherapy |
|---|---|---|
| What it is | An oral, small-molecule inhibitor targeting MET for patients with MET exon 14 skipping mutations or MET alterations in advanced NSCLC. | Standard combination chemotherapy using a platinum agent (such as cisplatin or carboplatin) with another drug for advanced NSCLC previously used in patients with MET alterations before targeted agents became available. |
| Role in the trial | The investigational treatment tested for safety and tumor response in adults with MET-altered advanced NSCLC. | Historically, the main treatment option for these patients before the emergence of MET inhibitors. |
| Primary use | To treat adults with advanced or metastatic NSCLC with MET exon 14 skipping mutations or MET alterations, especially for those who have failed previous systemic therapies or have limited standard options. | Previously used as the general first-line treatment for patients with advanced NSCLC, regardless of specific MET mutations, or as a fallback in those without access to MET-targeted therapy. |
| How it is given or performed | Given as a once-daily oral tablet while fasting, at a dose of 300 mg per day. | Typically administered as intravenous infusions in repeating cycles every 3 weeks, usually combining cisplatin or carboplatin with another cytotoxic drug. |
| Evidence status | Evidence for glumetinib is still maturing, with results from single-arm trials suggesting anti-tumor activity and manageable safety in MET-exon 14–mutated NSCLC, but randomized comparison data are lacking. | Supported by multiple large randomized trials and decades of practice, platinum-based chemotherapy has shown clinical benefit but generally lower response rates and shorter disease control when compared to targeted therapy in biomarker-selected NSCLC. |
| Important limitations | Efficacy results are based on a non-randomized single-arm trial without a direct comparator; activity may not predict survival advantage or broader real-world results. Long-term safety data and comparisons with approved targeted agents are also lacking. | Platinum-based chemotherapy is associated with significant toxicities, and in patients with specific MET alterations, response rates and progression-free survival are typically lower than with MET-targeted therapies, where available. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 year
Participants receive Glumetinib orally once daily while fasting as the selective MET inhibitor treatment for their advanced non-small cell lung cancer.
Regular visits during treatment as per protocol
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Huy Gia Vuong, An Thi Nhat Ho, Ahmed M A Altibi...
https://pubmed.ncbi.nlm.nih.gov/30089599/Yongfeng Yu, Wen Dong, Yanxia Shi...
https://pubmed.ncbi.nlm.nih.gov/39091606/Wanqing Chen, Rongshou Zheng, Peter D Baade...
https://pubmed.ncbi.nlm.nih.gov/26808342/Limei Yin, You Lu
https://pubmed.ncbi.nlm.nih.gov/30037377/Ahmedin Jemal, Rebecca Siegel, Jiaquan Xu...
https://pubmed.ncbi.nlm.nih.gov/20610543/Garrett M Frampton, Siraj M Ali, Mark Rosenzweig...
https://pubmed.ncbi.nlm.nih.gov/25971938/Yongfeng Yu, Jianya Zhou, Xingya Li...
https://pubmed.ncbi.nlm.nih.gov/37096188/Shun Lu, Yongfeng Yu, Jianya Zhou...
https://pubmed.ncbi.nlm.nih.gov/41132955/Joan H Schiller, David Harrington, Chandra P Belani...
https://pubmed.ncbi.nlm.nih.gov/11784875/Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram...
https://pubmed.ncbi.nlm.nih.gov/30207593/Haihe Biopharma Co., Ltd.
Lead Sponsor